CEP-11981 is under clinical development by Teva Pharmaceutical Industries and currently in Phase II for Adenocarcinoma. According to GlobalData, Phase II drugs for Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CEP-11981 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CEP-11981 overview
CEP-11981 is under development for the treatment of metastatic prostate cancer, metastatic hormone-refractory (castration-resistant, androgen-independent) prostate cancer, adenocarcinoma of the prostate, neuroendocrine gastroenteropancreatic tumors and pancreatic cancer. The drug candidate is administered through oral route. It acts by targeting VEGFR-1, 2, 3 (vascular endothelial growth factor receptor) and TIE2 (tyrosine kinase with immunoglobulin-like and EGF-like domains 2) kinase and FGFR1. It was also under development for the treatment of solid tumors and urothelial carcinoma (UC).
Teva Pharmaceutical Industries overview
Teva Pharmaceutical Industries (Teva) discovers, develops, manufactures, and commercializes generic and specialty medicines. The company provides specialty medicines to treat disorders of the central nervous system (CNS), cancer, respiratory, dermatology, women’s health, and other disease conditions. It offers generic medicines in various dosage forms including capsules, tablets, injectables, liquids, inhalants, creams, and ointments. Teva also provides over-the-counter (OTC) products, besides active pharmaceutical ingredients (APIs). It also focuses on developing generic drugs. The company conducts its worldwide operations through a network of subsidiaries in regions such as North America, Europe, and international markets. Teva is headquartered in Tel Aviv, Israel.
For a complete picture of CEP-11981’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
